Thrombospondin-1: A proatherosclerotic protein augmented by hyperglycemia

Journal of Vascular Surgery

Volumn 51, Issue 5, 2010, Pages 1238-1247

  Maier, Kristopher G ^a,c   Han, Xuan ^a,c   Sadowitz, Benjamin ^a,c   Gentile, Karen L ^b   Middleton, Frank A ^b   Gahtan, Vivian ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c VA Healthcare Network Upstate New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BONE MORPHOGENETIC PROTEIN; COLECALCIFEROL RECEPTOR; ENDOTHELIAL CELL GROWTH FACTOR; GLUCOSE; GLUCOSE TRANSPORTER 1; INTERLEUKIN 10; INTERLEUKIN 6; MANNOSE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTROPHIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN FOS; PROTEIN KINASE B; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; RNA; SERUM RESPONSE FACTOR; SMAD7 PROTEIN; SOMATOMEDIN C; SOS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; THROMBOSPONDIN 1; THYROID HORMONE RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA2; URIDINE DIPHOSPHATE GLUCOSE DEHYDROGENASE; THROMBOSPONDIN;

AORTA; ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; GENE AMPLIFICATION; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE; ANALYSIS OF VARIANCE; ANIMAL; CATTLE; CELL MOTION; COMPARATIVE STUDY; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; ATHEROSCLEROSIS; CATTLE; CELL MOVEMENT; CELLS, CULTURED; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; HYPERGLYCEMIA; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THROMBOSPONDINS; UP-REGULATION;

EID: 77952303791     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.11.073     Document Type: Article

References (39)

1. Wyne K. Information technology for the treatment of diabetes: improving outcomes and controlling costs. J Manag Care Pharm 2008;14: S12-7.
2. Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, et al. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008;31(Suppl 2):S155-60.
3. Chen D, Asahara T, Krasinski K, Witzenbichler B, Yang J, Magner M, et al. Antibody blockade of thrombospondin accelerates reendothelializa-tion and reduces neointima formation in balloon-injured rat carotid artery. Circulation 1999;100:849-54.
4. Brown C, Clark L, Williams L, Gallagher S, Levesque M, Silva J. Coronary restenosis. J Am Acad Nurse Pract 1996;8:283-8.
5. Lee T, Esemuede N, Sumpio BE, Gahtan V. Thrombospondin-1 induces matrix metalloproteinase-2 activation in vascular smooth muscle cells. J Vasc Surg 2003;38:147-54.
6. Roth JJ, Gahtan V, Brown JL, Gerhard C, Swami VK, Rothman VL, et al. Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. J Surg Res 1998;74:11-6.
7. Adams JC. Thrombospondin-1. Int J Biochem Cell Biol 1997;29: 861-5.
8. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 2001;107:929-34.
9. Esemuede N, Lee T, Pierre-Paul D, Sumpio BE, Gahtan V. The role of thrombospondin-1 in human disease. J Surg Res 2004;122:135-42.
10. Gahtan V, Wang XJ, Ikeda M, Willis AI, Tuszynski GP, Sumpio BE. Thrombospondin-1 induces activation of focal adhesion kinase in vascular smooth muscle cells. J Vasc Surg 1999;29:1031-6.
11. Gahtan V, Wang XJ, Willis AI, Tuszynski GP, Sumpio BE. Thrombospondin-1 regulation of smooth muscle cell chemotaxis is extracellular signal-regulated protein kinases 1/2 dependent. Surgery 1999;126:203-7.
12. Reed MJ, Iruela-Arispe L, O'Brien ER, Truong T, La Bell T, Bornstein P, et al. Expression of thrombospondins by endothelial cells. Injury is correlated with TSP-1. Am J Pathol 1995;147:1068-80.
13. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995;130:503-6.
14. Huang C, Kim Y, Caramori ML, Fish AJ, Rich SS, Miller ME, et al. Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system and diabetic nephropathy lesions in type 1 diabetes. Diabetes 2002;51:3577-81.
15. Belmadani S, Bernal J, Wei CC, Pallero MA, Dell'italia L, Murphy-Ullrich JE, et al. A thrombospondin-1 antagonist of transforming growth factor-{beta} activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am J Pathol 2007;171:777-89.
16. Raman P, Krukovets I, Marinic TE, Bornstein P, Stenina OI. Glycosyl-ation mediates up-regulation of a potent antiangiogenic and proathero-genic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. J Biol Chem 2007;282:5704-14.
17. Stenina OI, Krukovets I, Wang K, Zhou Z, Forudi F, Penn MS, et al. Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation 2003;107:3209-15.
18. Wahab NA, Schaefer L, Weston BS, Yiannikouris O, Wright A, Babe-lova A, et al. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mes-angial response to diabetic stimuli. Diabetologia 2005;48:2650-60.
19. Samuel SK, Hurta RA, Spearman MA, Wright JA, Turley EA, Green-berg AH. TGF-beta 1 stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluronan. J Cell Biol 1993;123: 749-58.
20. Vigetti D, Viola M, Karousou E, Rizzi M, Moretto P, Genasetti A, et al. Hyaluronan-CD44-ERK1/2 regulate human aortic smooth muscle cell motility during aging. J Biol Chem 2008;283:4448-58.
21. Ii M, Takenaka H, Asai J, Ibusuki K, Mizukami Y, Maruyama K, et al. Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ Res 2006; 98:697-704.
22. Levesque H, Girard N, Maingonnat C, Delpech A, Chauzy C, Tayot J, et al. Localization and solubilization of hyaluronan and of the hyaluronan-binding protein hyaluronectin in human normal and arteriosclerotic arterial walls. Atherosclerosis 1994;105:51-62.
23. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998;93:1159-70.
24. Hugo C. The thrombospondin 1-TGF-beta axis in fibrotic renal disease. Nephrol Dial Transplant 2003;18:1241-5.
25. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000;11:59-69.
26. Negoescu A, Lafeuillade B, Pellerin S, Chambaz EM, Feige JJ. Transforming growth factors beta stimulate both thrombospondin-1 and CISP/thrombospondin-2 synthesis by bovine adrenocortical cells. Exp Cell Res 1995;217:404-9.
27. Sakai K, Sumi Y, Muramatsu H, Hata K, Muramatsu T, Ueda M. Thrombospondin-1 promotes fibroblast-mediated collagen gel contraction caused by activation of latent transforming growth factor beta-1. J Dermatol Sci 2003;31:99-109.
28. Yevdokimova N, Wahab NA, Mason RM. Thrombospondin-1 is the key activator of TGF-beta1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol 2001;12:703-12.
29. Flugel-Koch C, Ohlmann A, Fuchshofer R, Welge-Lussen U, Tamm ER. Thrombospondin-1 in the trabecular meshwork: localization in normal and glaucomatous eyes, and induction by TGF-beta1 and dexamethasone in vitro. Exp Eye Res 2004;79:649-63.
30. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 1999;274:13586-93.
31. Kawataki T, Naganuma H, Sasaki A, Yoshikawa H, Tasaka K, Nukui H. Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma. Neuropathology 2000;20:161-9.
32. Shayman JA, Abe A. Glucosylceramide synthase: assay and properties. Methods Enzymol 2000;311:42-9.
33. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol 1998;18:1523-33.
34. Chatterjee SB, Dey S, Shi WY, Thomas K, Hutchins GM. Accumulation of glycosphingolipids in human atherosclerotic plaque and unaffected aorta tissues. Glycobiology 1997;7:57-65.
35. Mukhin DN, Chao FF, Kruth HS. Glycosphingolipid accumulation in the aortic wall is another feature of human atherosclerosis. Arterioscler Thromb Vasc Biol 1995;15:1607-15.
36. Mukhin DN, Prokazova NV. Neutral glycosphingolipid content and composition of cells from normal and atherosclerotic human aorta. Atherosclerosis 1992;93:173-7.
37. Singh NN, Ramji DP. The role of transforming growth factor-beta in atherosclerosis. Cytokine Growth Factor Rev 2006;17:487-99.
38. Abbas A, Grant PJ, Kearney MT. Role of IGF-1 in glucose regulation and cardiovascular disease. Expert Rev Cardiovasc Ther 2008;6: 1135-49.
39. Ezzat VA, Duncan ER, Wheatcroft SB, Kearney MT. The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes Metab 2008;10:198-211.